Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. (noted as Harrow, Inc. in metadata) on April 6, 2017, reporting events occurring on April 1, 2017. The filing details the entry into a material definitive agreement regarding intellectual property licensing.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The financial data provided is limited to the specific terms of the new license agreement:
- Royalty Rate: 3% to 6% of net sales of the licensed product.
- Milestone Payments: Three payments of $50,000 each, totaling $150,000, contingent on execution and sales thresholds.
- Payment Method: Cash or restricted common stock at the Company's election.
- Projected Non-Board Compensation: The Board does not expect total payments to the counterparty to exceed $120,000 in the next twelve months.
Material Changes
The primary material change is the execution of a License Agreement with Richard L. Lindstrom, M.D., a member of the Company's Board of Directors. The Company licensed the rights to develop, formulate, make, sell, and sub-license Klarity TM, a topical ophthalmic solution used to protect and rehabilitate the ocular surface.
Outlook, Risks, and Contingencies
Related Party Transaction: The agreement involves a Board member. The Board determined that the agreement would not impair Dr. Lindstrom's independence or his ability to provide independent oversight, though they will continue to monitor his status under Nasdaq rules.
Contingencies: Future financial obligations are contingent upon the Company achieving specific net sales milestones ($50,000 and $100,000) for the Product.
Unusual Items: The filing notes that the description provided is brief and refers to the full text of the agreement filed as Exhibit 10.1 for complete rights and obligations.
Investor Verification Checklist
- Verify the full text of the License Agreement (Exhibit 10.1) for detailed terms not summarized in the 8-K.
- Confirm the current independence status of Dr. Lindstrom on the Board following this transaction.
- Monitor future filings for the actual payment of the initial $50,000 milestone and any subsequent sales milestones.
- Review the press release (Exhibit 99.1) for additional commercial context regarding the Klarity TM product.